Where in the world? Clinical trial activity reveals competitor strategies
This article was originally published in Scrip
Executive Summary
The challenges of clinical development are well known, and ever increasing pressure to do more with less is not unique to this industry. Couple this pressure with lengthy development timelines and increasingly complex procedures and protocols, and development costs have soared over the past decade. Above all, trial recruitment remains the primary reason trials fail to complete on time and skyrocket beyond projected budgets.
You may also be interested in...
2011 Scrip 100: Novel drugs stage a comeback? Not exactly
For Phase II to Phase III trials started between October 2009 and September 2010, Novartis led the charge by some distance, with 144 studies heavily concentrated in autoimmune/inflammation and oncology. In fact, Novartis is among the top five sponsor rankings in every therapeutic area we examined, taking first place in autoimmune/inflammation and cardiovascular; second place in oncology, CNS and infectious disease; and third in metabolic/endocrinology.